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Abstract
With the aim to develop an efficient and cost-effective approach to control malaria, we have generated porcine parvovirus-
like particles (PPV-VLPs) carrying the CD8
+ T cell epitope (SYVPSAEQI) of the circumsporozoite (CS) protein from Plasmodium
yoelii fused to the PPV VP2 capsid protein (PPV-PYCS), and tested in prime/boost protocols with poxvirus vectors for efficacy
in a rodent malaria model. As a proof-of concept, we have characterized the anti-CS CD8
+ T cell response elicited by these
hybrid PPV-VLPs in BALB/c mice after immunizations with the protein PPV-PYCS administered alone or in combination with
recombinant vaccinia virus (VACV) vectors from the Western Reserve (WR) and modified virus Ankara (MVA) strains
expressing the entire P. yoelii CS protein. The results of different immunization protocols showed that the combination of
PPV-PYCS prime/poxvirus boost was highly immunogenic, inducing specific CD8+ T cell responses to CS resulting in 95%
reduction in liver stage parasites two days following sporozoite challenge. In contrast, neither the administration of PPV-
PYCS alone nor the immunization with the vectors given in the order poxvirus/VLPs was as effective. The immune profile
induced by VLPs/MVA boost was associated with polyfunctional and effector memory CD8+ T cell responses. These findings
highlight the use of recombinant parvovirus PPV-PYCS particles as priming agents and poxvirus vectors, like MVA, as
booster to enhance specific CD8+ T cell responses to Plasmodium antigens and to control infection. These observations are
relevant in the design of T cell-inducing vaccines against malaria.
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Introduction
The development of a malaria vaccine is a major goal in the
fight against infectious diseases, as infection with Plasmodium
falciparum causes an estimated 225 million cases of malaria and
781,000 deaths from the disease worldwide, mostly among
children in Africa [1]. Progress in this direction has been obtained
with the demonstration in phase 2 clinical trials that the
administration of an anti-sporozoite vaccine based on the parasite
CS protein fused with the hepatitis B antigen (referred as RTS,S)
in combination with the adjuvants AS01 and AS02 generates in
children and infants around 50% clinical efficacy against malaria
[2,3,4] [5]. Immunological analysis indicates that the likely main
protective mechanism is the induction of antibodies against the CS
protein, while CD8+ T cell responses might play a minor role as
they are very modest [4,6]. The combination of anti-CS antibody
concentrations titers and CS-specific TNFa(+) CD4(+) T cells
could account for the about 50% level of protection against clinical
malaria conferred by RTS,S/AS01(E) [4,7]. Based on the CS-
protective efficacy, a phase III clinical trial is ongoing in 11 centers
in Africa with RTS,S (NCT00866619). Thus far, initial results of
this trial at 12 months provided about 50% reduction of clinical
episodes of malaria and severe malaria in vaccinated children 5 to
17 months of age [8]. The limited protection thus far obtained
with the RTS,S vaccine, suggest the need to improve the efficacy
of this malaria vaccine.
Because both B and T cell responses might be required for the
control of Plasmodium infection, it could be beneficial for the
current RTS,S vaccine to also enhance CD8+ T cell responses.
Numerous protocols have been developed that trigger specific B
and T cell responses to Plasmodium antigens with different
degrees of protection in animal models, using a combination of
viral and non viral vectors [9]. Among vaccine protocols, the
heterologous prime/boost immunization using poxvirus vectors as
booster has been shown to be quite effective at inducing T cell
responses with protection in animal model systems. In fact,
influenza and VACV vectors both expressing the CS antigen of
Plasmodium yoelii (P. yoelii), provided evidence in mice that the
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inducing specific CD8+ T cell responses and high levels of
protection against rodent malaria, and that the order of vector
immunization was critical [10]. The question of which are the
most appropriate vectors for use in human trials is still unclear and
is based on several assessments in which nature of antigens,
immune potency, durability, efficacy, safety and cost play
important roles. Recently, a combination of poxvirus vectors
(fowlpox and MVA) expressing different Plasmodium antigens has
shown lack of protection in phase I/IIa clinical trials [11], and this
could be related to the complex nature of the six pre-erythrocytic
malaria antigens linked together in a single protein. The use of
single protein components as immunizing agents that can prime
an anti-malaria immune response which is expanded after a boost
with a poxvirus vector could be a favorable option to avoid antigen
competition. Proteins can be delivered either alone, conjugated
with adjuvants, in the form of fusion polypeptides or as part of
virus-like particles (VLPs).
The use of VLPs might be preferable due to the ease of
production and of presentation of the malaria antigen, as the VLPs
behave as native virus particles during entry and processing into
antigen-presenting cells. It has been previously demonstrated that
chimeric PPV-VLPs carrying heterologous epitopes, when injected
intraperitoneally (i.p) into mice, activate strong CD4+ and CD8+
T-cell responses specific for the foreign epitopes, and these
responses are mediated by dendritic (DC) cells and influenced by
the flanking sequences [12,13,14]. PPV-VLPs are formed by the
assembly of 60 copies of the major virus capsid protein (VP2) of
PPV [15]. PPV-VLPs have been engineered to deliver CD8+ T-
cell epitopes [12] or CD4+ T cell helper epitopes [16] inserted into
the N terminus of the PPV VP2. Cytotoxic T lymphocyte (CTL)
response was characterized by a high frequency of specific T cells
of high avidity [17]. Moreover, the CTL activation does not
require CD4+ T cell help [12]. PPV-VLPs are captured by DC
through macropinocytosis and these cells are the only antigen
presenting cells (APCs) for PPV-VLPs [13]. VLPs can be found in
the endosome of DC, where processing of the epitopes inserted in
the VLPs takes place [13]. In addition, B cell epitopes can be
engineered on the surface of the parvovirus VLPs by manipulating
the VP2 loops to elicit a potent antibody response [18].
Thus, to enhance the CD8+ T cell response of a CS-based
immunization procedure, in this investigation we compared in
mice the immunogenicity and anti-malaria efficacy of protocols
based on priming with parvovirus PPV-VLPs carrying a CD8+ T-
cell epitope from the P. yoelii CS protein, restricted by the H-2K
d
molecule (SYVPSAEQI) and boosted with either a recombinant
replication competent (WR strain) or replication restricted (MVA
strain) of VACV, both vectors expressing the entire P. yoelii CS
protein.
Results
The CS-T cell priming effect induced by PPV-PYCS VLPs is
markedly enhanced by boosting with a replication
competent VACV vector
Recombinant PPV-VLPs have been shown to be effective
delivery systems of heterologous sequences that trigger specific
Th1 type of immune responses to the foreign epitopes when
inoculated in animal models [12,16]. With the aim to define the
priming capacity of PPV-VLPs in prime/boost combination of
immunogens, we generated recombinant PPV-VLPs by the
insertion into PPV VP2 of the specific CD8+ T cell epitope
(SYVPSAEQI) from P. yoelii CS protein, restricted by the H-2K
d
molecule [10]. A DNA fragment coding for the CS epitope was
fused to the 59-end of the gene coding for PPV VP2 capsid protein.
This chimeric gene, when expressed by the baculovirus system,
produces a CS epitope-VP2 fusion protein that self assembles
generating PPV-PYCS VLPs that can be easily purified (Figure 1).
Production and purification of PPV-PYCS from baculovirus
infected insect cells was performed as described under Materials
and Methods. Figure 1A shows a coomassie blue stained SDS-
PAGE of the purified PPV-PYCS. A main single band of about
67 kDa was observed on the gel, indicating high purity of the
recombinant protein. This was also confirmed by electron
microscopy as shown by a photomicrograph of the purified VLPs
in Figure 1B. To study the ability of PPV-PYCS to induce a
specific anti-CS T cell immune response, and to test whether the
achieved immune response could be enhanced after booster with a
replication competent VACV recombinant from WR strain
expressing the complete CS protein (VV-PYCS), we immunized
groups of BALB/c mice (5 per group) with PPV-PYCS given
subcutaneously (s.c) (10 or 50 mg/ per mouse), and boosted
14 days later with 10
7 pfu/mouse of VV-PYCS by the same route.
At 14 days after the booster, splenocytes from immunized animals
were subjected to a standardized and quantitative ELISPOT
assay, measuring IFN-c secreting cells [19]. We used MHC-class I
P815 cells (H-2
d) as APC, pulsed with 10
26 M of the synthetic
peptide SYVPSAEQI, corresponding to the P. yoelii CS protein.
Previous studies have shown the CD8+ T cell responses of the P.
yoelii CS-peptide (SYVPSAEQI), which is specific for IFN-c
secreting cells [10] [20]. As shown in Figure 2, animals immunized
with two doses of 10 mg of PPV-PYCS did not develop a
significant CS-specific CD8 T cell response. However, when
animals were boosted with a VV-PYCS a significant (p,0.001;
one-way ANOVA) increase in the response was observed. This
increment was dose-dependent, since animals primed with the
highest dose of PPV-PYCS (50 mg) developed the strongest
response. In addition, this response was specific, as a non-related
recombinant VACV expressing luciferase when used for booster
(VV-LUC) had no effect on T cell responses. These findings
revealed that while PPV-PYCS per se is low inducer of IFN-c
secreting cells, however, is an effective priming component when
booster is done with the replication competent VV-PYCS
recombinant vector.
Priming with PPV-PYCS followed by booster with
replication competent VV-PYCS protects mice against
liver stage parasites after challenge with P. yoelii
To determine whether PPV-PYCS prime/VV-PYCS boost
immunization could induce protective immunity against pre-
erythrocytic stages of the parasite, BALB/c mice (5 per group)
were immunized with 10 or 50 mg of PPV-PYCS administered s.c
and 2 weeks later were boosted with one dose of 10
7 pfu of VV-
PYCS administered by the s.c route. Thereafter, immunized mice
were challenged i.v with 5x10
5 P. yoelii highly infective sporozoites.
Parasite development was monitored at 42 h after challenge by
measuring plasmodial rRNA in the liver of the challenged mice by
semi-quantitative RT-PCR assay, a well defined and standardized
protocol to evaluate protection [10,21]. We found that mice
immunized following the prime-boost immunization scheme had
very low levels of the parasite load in the liver, with an 86%
percent reduction when the dose of PPV-PYCS was 50 mg and
81% reduction in parasitemia with a dose of 10 mg (Figure 3;
p,0.001 by one-way ANOVA). Mice immunized with either two
doses of PPV-PYCS or VV-PYCS showed a partial decrease of the
parasite load in the liver in comparison with non-vaccinated
control mice. These findings showed that administration of PPV-
VLPs alone does not protect against sporozoite challenge while the
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control P. yoelii infection.
Booster with a replication-restricted MVA-PYCS vector
triggers strong CD8+ T cell responses to CS after priming
with PPV-PYCS
While studies shown in Figures 2 and 3 were performed with
replication competent VACV, it was of interest to know to what
extent the use of a replication restricted and highly attenuated
vector like MVA [22] could boost PPV based anti-malaria
immune response. Thus, groups of BALB/c mice (5 per group)
were primed s.c with different doses of PPV-PYCS (10, 50 and
100 mg) and two weeks later those mice were boosted s.c with
10
7 pfu of the attenuated MVA-PYCS vector. A group of mice
immunized with 50 mg of PPV-PYCS and boosted with 10
7 pfu of
VV-PYCS was included as comparison for replication competent
vector. Also groups of mice primed/boosted with 100 mg of PPV-
PYCS, or primed with PPV-VLPs lacking the CS-specific CD8+ T
Figure 1. Characterization of PPV-PYCS VLPs. Conditions for generation of the PPV vector expressing the specific CD8+ T cell epitope of P. yoelii
CS, growth in baculovirus-infected insect cells and purification of the PPV-VLPs is described under Materials and Methods. (A). Proteins were resolved
by 9% SDS-PAGE and visualized after coomassie-blue staining. Molecular masses of standard proteins (lane 1) are indicated at the left. Lane 2, shows
partial purification and lane 3, purified protein with the size corresponding to the PPV VP2. (B). Electron microscope image of negatively stained PPV-
PYCS VLPs.
doi:10.1371/journal.pone.0034445.g001
Figure 2. The CS-specific CD8+ T-cell priming effect of PPV-
PYCS is markedly enhanced by boosting with replication
competent VACV vector expressing CS. Different groups of
BALB/c mice (5 per group) were immunized s.c with 10 or 50 mgo f
PPV-PYCS [PPV(10 mg) and PPV(50 mg) respectively] or with VACV
vectors in prime/boost protocols. Fourteen days after the boost CS-
specific IFN-c secreting cells for the plasmodial epitope SYVPSAEQI in
splenocytes were measured by ELISPOT as described under Materials
and Methods. The results are expressed as the mean of triplicate assays
using cultured pooled splenocytes. Statistical values were determined
by one-way ANOVA; P values, *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0034445.g002
Figure 3. Protective capacity of PPV-PYCS prime followed by
booster with replication competent VACV vector expressing
CS. Groups of BALB/c mice (5 per group) were immunized with
different amounts of PPV-PYCS [PPV(10 mg) and PPV(50 mg)] or non-
vaccinated and two weeks later animals were boosted with the
replication competent VACV vector from the WR strain (referred as VV-
PYCS) or with PPV-PYCS. Thirteen days later, animals were challenged
with sporozoites and the amount of parasite rRNA in the liver of each
animal was estimated 42 h after the challenge, as described under
Materials and Methods. Results are expressed as the mean with
standard deviation. Statistical values were determined by one-way
ANOVA; P values, *P,0.05, **P,0.01, ***P,0.001. Lane (–), non-
vaccinated.
doi:10.1371/journal.pone.0034445.g003
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reference. The frequencies of ex vivo splenocytes producing IFN-c
upon MHC class-I restricted peptide stimulation was determined
by ELISPOT assay two weeks later. As shown in Figure 4, the
groups of animals receiving PPV-PYCS/MVA-PYCS had the
highest values of IFN-c secreting cells (p,0.001 by one-way
ANOVA). These values were even higher than those observed in
the group PPV-PYCS/VV-PYCS. Significantly, a low immune
response was obtained when single dose of MVA-PYCS was used,
or when it was given after priming with non-recombinant VLPs.
In addition, a minor immune response was obtained when PPV-
PYCS was used at 100 mg/per dose (Figure 4).
These findings clearly demonstrate that priming with PPV-
PYCS is necessary to activate specific T cells, but to obtain large
expansion of these T cells it required MVA-PYCS boost.
Protection against parasites after prime/boost with PPV-
PYCS/MVA-PYCS protocol
Next we examined if the increase in immune response observed
after MVA-PYCS boost is translated into a high degree of
protection. In this experiment we compared the protective
immunity elicited against parasite challenge after prime-boost
immunization with PPV-PYCS followed by VV-PYCS or MVA-
PYCS, with that obtained in a group of mice immunized with a
recombinant influenza virus expressing P. yoelii CS-CD8+ T cell
epitope (Flu-PYCS) and boosted with VV-PYCS. As shown in
Figure 5 the degree of protection, based on reduced parasitic
burden in the liver, was higher in the group of mice primed with
PPV-PYCS and boosted with MVA-PYCS than in the group of
mice boosted with VV-PYCS (p,0.001 by one-way ANOVA. On
the other hand the 97% inhibition of parasite development in the
group of mice boosted with MVA was similar to that obtained in
the group of mice immunized with Flu-PYCS/VV-PYCS which
serves as a reference, as it is a well established and standardized
protocol previously described to induce high level protection after
parasite challenge [10]. These findings demonstrate the high
degree of protection against liver stage parasites obtained by a
PPV/MVA regime.
PPV-PYCS priming followed by MVA-PYCS boost
improved the polyfunctionality and magnitude of
memory CD8 T-cell responses
Enhancement in the quality and magnitude of memory CD8+ T-
cell response is known to correlate with better protection in malaria
[23,24]. Therefore, to define the CD8+ T cell responses induced by
VLP-PYCS/MVA-PYCS prime-boost, we performed intracellular
cytokine staining (ICS) study with splenocytes obtained from mice
immunized by various protocols and collected 53 days post-boost to
evaluate memory T cells. The vaccination regime based on VLP-
PYCS prime/MVA-PYCS boost generated a robust response in
mice when compared to VLP-PYCS prime/boost or DNA-PYCS/
MVA-PYCS prime/boost, as revealed after separation of CD8 T-
cells based on memory markers CD127 and CD62L (Figure 6).This
approach helped to differentiate TEffector;T E (CD127
LoCD62L
Lo),
TEffector Memory;T EM (CD127
HiCD62L
Lo) and TCentral Memory;T CM
(CD127
HiCD62L
Hi). Considering the negligible CD8+ T-cell
responses generated when using DNA-PYCS as priming agent, a
VLP-PYCS/MVA-PYCS vaccine regime elevated the CS specific
Figure 4. Booster with replication restricted MVA-PYCS vector
triggers strong CS CD8+ T-cell response after priming with
PPV-PYCS. Groups of BALB/c mice (5 per group) were immunized s.c
with different amounts of PPV-PYCS [PPV(10 mg), PPV(50 mg)
PPV(100 mg)], with non-recombinant PPV-VLPs (nrPPV) or with VACV
vectors (VV-PYCS or MVA-PYCS) in prime/boost protocols and 14 days
after the boost CS-specifc IFN-c secreting cells for the plasmodial
epitope SYVPSAEQI in splenocytes were measured by ELISPOT as
described under Materials and Methods. Purified PPV-VLPs without the
peptide insert were used as control. The results are expressed as the
means of assay triplicates of cultured pooled mouse splenocytes.
Statistical values were determined by one-way ANOVA; P values,
*P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0034445.g004
Figure 5. Protection against malaria after prime/boost with
PPV-PYCS/MVA-PYCS protocol. Groups of BALB/c mice (5 per
group) were immunized with different amounts of PPV-VLPs
[PPV(10 mg) and PPV(50 mg)] and two weeks later animals were boosted
with the replication restricted MVA-PYCS or the replication competent
VV-PYCS. A positive control group primed with an influenza virus
recombinant expressing the CD8+ T cell epitope and booster with VV-
PYCS, a protocol previously shown to induce high protection against
the parasite, was included [10]. Thirteen days later, animals were
challenged with sporozoites and the amount of parasite rRNA in the
liver of each animal was estimated 42 h after the challenge, as
described under Materials and Methods. Results are expressed as the
mean with standard deviation. Statistical values were determined by
one-way ANOVA; P values, *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0034445.g005
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(Fig 6). Interestingly, the majority of the CD8+ T cells, following
stimulation, rapidly acquired TE phenotype. However a significant
increase in the TEM population was also observed (Fig 6).
Furthermore, the polyfunctional nature of the CD8 T-cells
generated, suggested the enhanced capability of VLP priming
followed by VACV boost. The majority of the CD8 cells produced
were double positive for IFN-c and TNF-a (IFN-c
+TNF-a
+)
(p,0.001) (Figure 7). In addition, there was high surge in the
TNF-a secreting cells (p,0.005). Although, at lower levels, there
was a significant induction of triple positive cytokine secreting cells
(IFN-c
+TNF-a
+IL-2
+)( p,0.001). Thus, the data revealed how
VLP-PYCS prime/MVA-PYCS boost improves the polyfunction-
ality and the population of memory CD8+ T cells in immunized
mice, immune parameters which might be relevant in protection
against malaria.
Discussion
While one of the main interests in the malaria vaccine field is to
develop immunogens based on proteins for safety considerations,
however, the immune response triggered by proteins is generally
weak with a bias for Th2 type. Thus, efforts have been directed to
combine proteins with adjuvants and immunostimulatory mole-
cules, to enhance specific innate immune responses and to drive
the response to a Th1 type. In fact, the current phase III clinical
trial with malaria vaccine RTS,S is based on CS protein fused to
hepatitis B antigen and combined with a potent adjuvant AS01.
Because previous studies with the RTS,S vaccine have shown
Figure 6. PPV-PYCS/MVA-PYCS prime/boost improves cytokine secretion by memory CD8
+ T-cells. Groups of BALB/c mice (4 per group)
were immunized in prime/boost as indicated in Table 1 and 53 days post boost splenocytes were processed for ICS as described under Materials and
Methods. Phenotypic differentiation of CD8
+ T-cells based on memory markers CD127 (V450) and CD62L (FITC). Each quadrant represents different
memory population of CD8 cells with its respective percentages. The distribution of antigen specific CD8+ T-cells secreting cytokines in response to
CS peptide stimulation, within the different memory population is also shown. The total CD8+ T-cell response is indicated by the black boxes. The
boxes on left indicate the responses towards CS peptide stimulation while the ones on right represent its respective RPMI controls.
doi:10.1371/journal.pone.0034445.g006
Vaccine Efficacy against Malaria by VLPs/Poxvirus
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34445weak CD8+ T cell responses in vaccinees, in this investigation we
have asked the question as to what extent CS antigen presentation
by chimeric VLPs obtained from PPV is able to prime CD8+
T cell responses, and how these responses can be enhanced when
combined with poxvirus vectors expressing CS. In addition, we
have asked in which grade specific CD8+ T cell immune responses
are associated with protection against malaria and what are the
CD8+ T cell populations induced. This proof-of-concept has been
tested in mice. In this work we have generated recombinant
parvovirus-derived VLPs expressing the CTL epitope from the P.
yoelii CS protein.
The PPV-VLP system presents several advantages such as the
long term stability of VLPs in addition to high levels of protein
expression. Although the system has not been rigorously tested for
the largest insert size that can be accommodated without
disrupting the particle, there would be two ways to overcome
the limitation of the system to accept large insertions. First, it is
relatively simple to build different PPV-VLPs containing different
CD8+ epitopes that can be mixed during administration. Second,
PPV VP2 containing different epitopes can be co-expressed in the
baculovirus system to prepare VLPs with mixtures of different
epitopes. These possibilities would facilitate the use of multiple
CD8+ epitopes, as required for human vaccines, or their
combination with CD4+ or B cell epitopes. These combinations
should result in a more efficient vaccine design.
Groups of mice immunized in a prime/boost regimen with two
doses of PPV-PYCS did not develop significant anti-CS cellular
immune response, determined by the ELISPOT assay. However,
when animals were immunized with different doses of PPV-PYCS,
followed by the recombinant VV-PYCS, expressing the full CS
protein from P. yoelii, a strong CD8
+ T cell response was generated
against this antigen. This response was about 10 times higher that
the one obtained with two doses of VV-PYCS. When we used for
priming two different doses (10 and 50 mg) of PPV-PYCS followed
by a booster with 10
7 PFU of VV-PYCS there was a dose response
effect, obtaining the highest CD8+ T cell response with the highest
dose of PPV-PYCS. In this experiment we observed again that this
response was much higher than that obtained with two doses of
VV-PYCS. We have also included as control a non-related
recombinant VACV for booster, which showed that the CD8+ T
cell response primed by the recombinant VLPs is boosted in an
antigen dependent manner, and cannot be boosted by a non-
related VACV recombinant.
Importantly, when we analyzed protection after challenge with
the parasite in animals immunized as described above, quantified
as reduction in the amount of Plasmodium rRNA in the liver with
respect to non-immunized animals, we observed maximal
protection in mice primed with PPV-PYCS followed by a booster
with VV-PYCS or MVA-PYCS. Because safety is a major concern
for developing poxvirus based vaccines, we included for boosting a
recombinant vector expressing the full-length CS protein based on
the highly attenuated MVA strain instead of the recombinant
based on replicating WR strain. When mice were immunized with
10, 50 or 100 mg of PPV-PYCS followed by the MVA
recombinant (10
7 pfu), we obtained a stronger cellular immune
response that was about 2 to 3 times higher than that obtained
when we used for boosting a recombinant based on the WR strain.
While two doses of PPV-PYCS did not elicit significant cellular
immune responses, these PPV-VLPs were able to prime a specific
anti-CS CD8+ T cell response that could be subsequently be
boosted by MVA-PYCS. When PPV-PYCS was substituted by
PPV-VLPs without the CS epitope during priming, the magnitude
of the response after booster with the virus was similar to that
obtained with only one dose of MVA-PYCS.
The magnitude of the specific cellular immune response was
associated with protection, defined by markedly reduced parasites
Figure 7. Polyfunctionality of CD8+ T-cells is improved by heterologous prime/boost. Groups of BALB/c mice (4 per group) were
immunized in prime/boost as indicated in Table 1 and 53 days post boost splenocytes were processed for ICS as described under Materials and
Methods. Memory CD8 T-cells were differentiated into single, double or triple positive cells secreting IFN-c (PeCy7), TNF-a (PE) and IL-2 (APC).
Polyfunctionality is indicated by the pie chart.The data was then analyzed using SPICE software. Data are expressed as mean 6 s.e. (n=4 mice per
group). Statistical values were determined by a novel approach previously described (33). P values were calculated between PPV/MVA-PYCS and PPV/
PPV groups. **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0034445.g007
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immunized as before were challenged with the Plasmodium
parasite, maximal protection was observed in animals boosted with
the MVA-PYCS recombinant. The high protection (about 95%)
obtained after priming with PPV-PYCS and boosting with MVA-
PYCS was comparable to that obtained after immunization in
similar prime/boost approach but using instead two live
recombinant viral vectors, i.e influenza expressing the CD8
+ T
cell epitope followed by VV-PYCS, that we have previously
reported to be protective [10]. This is an important consideration,
since by using PPV-VLPs and MVA immunogens we are able to
achieve similar protective immune response than previously
attained with two replicating viral vectors.
How can we explain the enhanced response obtained by PPV-
VLPs/poxvirus prime/boost approach and its association with
protection against the malaria parasite? Based on current
understanding of prime/boost protocols, and due to the induction
of anti-vector immunity by the VACV prime, we suggest that
during priming with PPV-PYCS the particles which are able to
enter the cells, are processed by antigen presenting cells and
trigger an innate immune response that activate T cells; after
booster the primed T cells are expanded as a result of infection of
antigen presenting cells by MVA-PYCS and cross-priming effects
by induction of apoptosis [25]. In addition, the innate immune
response triggered by MVA [26] can also be responsible for T cell
expansion. Significantly, the T cell responses observed in the two
protocols PPV/VV and PPV/MVA were associated with high
levels of protection against the parasite, while low levels of T cells
were ineffective to control the parasite. While it is difficult to
compare immune correlates between studies performed with
different vectors, the magnitude of CD8+ T cell responses after the
PPV-VLPs prime/pox boost and degree of protection against the
parasite in this study are remarkable. In fact, analysis of the
memory CD8+ T cells after prime/boost revealed that the
protocol VLP/MVA induced a polyfunctional response with
activation of effector memory CD8+ T cells, both immune
parameters that could be relevant in protection against malaria
[24].
While a number of different prime/boost combination of
vectors expressing malaria antigens have shown activation of
CD8+ T cell responses and different degrees of protection against
murine malaria [9,27], [28] there are several advantages in the use
of PPV-VLPs and MVA vectors expressing the CS antigen for T
cell activation. First, CS has shown good immunogenicity profile
with efficacy in preclinical assays whether from DNA, Ty-particles,
a fusion protein or delivered by viral vectors, but most importantly
when fused with hepatitis B antigen plus an adjuvant it induced
significant protection in children exposed to malaria, indicating
the CS protective capacity if formulated properly for immune B
and T cell activation. Second, expression of CS as part of PPV-
VLPs is able to prime the antigen presenting cell in a way that
further booster with the poxvirus vector MVA triggered high levels
of CD8+ T cells, which are polyfunctional and of effector memory
phenotype, that are associated with high degree of protection after
challenge when evaluated by liver stage parasite inhibition. Third,
both vectors PPV-VLPs [29] and MVA recombinants [22] can be
easily grown to large scale for vaccination purposes. Future studies
on potential clinical applicability of the the PPV-VLP platform will
require to define if these capsids are capable of carrying large
regions of antigen or carrying multiple T-cell epitopes which
diverse humans will respond.
Overall, the results reported here demonstrate that prime/boost
immunization with PPV-VLPs and MVA expressing CS is a
logical vaccine approach to optimize cellular immunity and
protection against malaria. These findings are relevant in the
design of vaccine strategies against Plasmodium.
Materials and Methods
Ethics Statement
The animal studies were approved by the Ethical Committee of
Animal Experimentation (CEEA-CNB) of Centro Nacional de
Biotecnologia (CNB-CSIC, Madrid, Spain) in accordance with
national and international guidelines and with the Royal Decree
(RD 1201/2005), permit number: 130/07.
Cells
African green monkey kidney cells (BSC-40; ATCC CRL-2761)
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% newborn calf serum (NCS). Chick
embryo fibroblast (CEF) cells were obtained from sterile
pathogen-free eggs provided by INTERVET (Salamanca, Spain),
and primary cultures were prepared according to standard
procedures and maintained in DMEM supplemented with 10%
fetal calf serum (FCS) (GibcoH, Grand Island, NY, USA). P815
(ATCC TIB-64) mastocytoma cells that express MHC class I
molecules H-2d were cultured in DMEM containing 10% FCS.
Spodoptera frugiperda clone 9 (Sf9, CRL 1711, ATCC) cells were
grown and maintained in suspension at 27uC using Grace’s insect
tissue culture medium (GibcoH, Grand Island, NY, USA)
supplemented with 10% FCS, 0.2% Pluronic F-68 (Sigma-Aldrich,
Steinheim, Germany) and antibiotics.
Growth and purification of VACV expressing the CS
protein from P. yoelii
The recombinant VACV virus VV-PYCS carrying in the TK
locus the entire CS gene of P. yoelii, has been previously described
[10]. To generate the recombinant virus MVA-PYCS, the CS
gene was inserted by homologous recombination into the TK
region of the genome of the MVA strain, by using the VV transfer
plasmid pSC-PYCS containing the CS DNA sequence under the
control of the VACV p7.5 promoter. b-galactosidase-producing
plaques were picked, cloned three times, and amplified in CEF
cells as previously described [21]. VV-PYCS and MVA-PYCS
were propagated and titrated in monkey BSC-40 and CEF cells
respectively [30]. Both viruses were purified by banding in sucrose
gradients, as previously described [31].
Construction of a recombinant baculovirus expressing
PPV-PYCS
Oligonucleotide 59-TCGAGATGTCATACGTTCCCTCGG-
CCGAACAAATCC-39 and its complementary 59-TCGAG-
GATTTGTTCGGCCGAGGGAACGTATGACATC-39 were
designed in order to regenerate the PYCS CD8 epitope
SYVPSAEQI plus an initiation codon and two cohesive XhoI
sites. The oligonucleotides were phosphorylated with T4 polynu-
cleotide kinase, annealed at 70uC for 15 min and ligated into XhoI-
digested pPPV29mod, which contains a unique XhoI restriction
site immediately downstream of the initiation codon of the PPV
VP2 gene, as previously described [12]. Then, the chimeric VP2
sequence containing the PYCS epitope was isolated by BamHI
digestion and subcloned into BamHI-digested pAcYM1. The
recombinant baculovirus transfer vector was called pAcYM1-
PPV-PYCS.
The recombinant viruses were obtained by cotransfection of
Spodoptera frugiperda (Sf9) insect cells with a mixture of 2 mgo f
purified transfer vector DNA plus 500 ng of parental BacPAK6
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presence of cationic liposomes [18]. Transfected cultures were
collected when the cells started to show signs of infection, usually
5–6 days later. Recombinant baculoviruses were plaque-purified
in the presence of X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galac-
topyranoside) until no more blue plaques (wild-type) were
detected. Then, high-titers stocks (.10
8 pfu/ml) of the recombi-
nant baculovirus AcPPV-PYCS were obtained.
Characterization and purification of PPV-PYCS VLPs
Sf9 cells were infected with AcPPV-PYCS at a multiplicity of
infection of 0.5 plaque-forming units (pfu) per cell. Cells were
collected at 72 h post-infection with a clear cytophatic effect.
Purification of PPV-VLPs was carried out as previously described
[12,16]. Briefly, infected Sf9 cells were lysed by hypotonic shock
with 25 mM bicarbonate solution at 4uC. Cell debris was removed
by centrifugation and the PPV-VLPs present in the supernatant
were precipitated with 20% ammonium sulfate, resuspended in
PBS and dialysed. The purity of the preparation of PPV-PYCS
VLPs was confirmed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Protein concentration was estimated
by densitometric assay with the Bio-Rad protein assay reagent,
and using BSA as reference.
Recombinant baculovirus, AcPPV-PYCS, which express under
the polyhedrin promoter the PPV VP2 capsid protein fused at its
amino-terminus with the PYCS CD8+ epitope, was used for
antigen preparation.
Plasmid construction
pCI-Neo-CS. The gene coding for P. yoelii CS protein was
amplified from MVA-PYCS using the primers CS-XhoI-F (59-
ACTTACTCGAGATGTGTTACAATGAAGAAAATG-39) and
CS-NotI-R (59-ATTGCGGCCGCTTTAAAATATACTTGAAC-
39) to yield a 972 bp fragment lacking the N-terminal signal
sequence and C-terminal GPI sequence. The gene was inserted
into a mammalian expression vector, pCI-Neo, that had been
previously digested with XhoI and NotI followed by SAP treatment
(Shrimp Alkaline Phosphatase). The CS gene in both the virus and
plasmid were sequenced (Secugen; Spain). The plasmid was
purified using Qiagen Mega Prep Kit according to manufacturer’s
protocol. Expression of CS from pCI-Neo-CS was confirmed by
transfecting DF-1 cells followed by western blot analysis with CS
specific antibodies.
Parasites
P. yoelii (17XNL strain) was maintained by alternating passages
in Anopheles stephensi mosquitoes and Swiss Webster mice.
Sporozoites were collected through infected mosquito’s salivary
glands dissection.
Immunization of mice and challenge
Six to eight weeks old female BALB/c mice (Harlan), were used
for immunization purposes. Both, PPV-PYCS and recombinant
viruses, resuspended in sterile PBS, were injected subcutaneously
(s.c). Immunization schedules (dose, route, number of mice) are
indicated in Table 1. Non-immunized and immunized mice were
challenge 13 days after the booster by inoculation of 5610
5 P.
yoelii sporozoites by the intravenous (i.v) route into the mouse tail
vein.
ELISPOT assay
The ELISPOT assay was used to detect epitope-specific IFN-c-
secreting cells [19]. Briefly, nitrocellulose-bottomed 96-well plates
were coated with anti-mouse IFN-c mAb R4-6A2 (8 mg/ml,
Pharmingen, San Diego, CA). After overnight incubation at room
temperature, wells were washed three times with RPMI 1640, then
100 ml of medium supplemented with 10% FCS were added to
each well, and plates incubated at 37uC for 1 h. Triplicate cultures
were prepared with serial doubling dilutions of immunized
splenocytes, beginning with 10
6 cells/well. P815 cells (H-2
d), used
as antigen-presenting cells (APC), were pulsed with 10
26 M of the
synthetic peptide SYVPSAEQI, corresponding to the P. yoelii CS
protein, and treated with mitomycin C (30 mg/ml, Sigma). After
several washes with culture medium, 10
5 P815 cells were added to
each well. Control P815 cells were not pulsed with the peptide.
Plates were incubated for 26–28 h at 37uC, washed with PBS
containing 0.05% Tween-20 (PBS-T) and incubated overnight at
4uC with biotinylated anti-mouse IFN-c mAb XMG1.2 (2 mg/ml,
Pharmingen) in PBS-T. Plates were washed with PBS-T and
peroxidase-labeled avidin (Sigma; 100 ml, 1/800 dilution in PBS-
T) was added to each well. One hour later, wells were washed with
PBS/T and PBS. Spots were developed by adding 50 mM Tris-
HCl, pH 7.5 containing 1 mg/ml of 3,39-diaminobenzidine
tetrahydrochloride (Sigma) and 0.015% H2O2. When the plates
were completely dry, the number of spots was determined with the
aid of a stereomicroscope.
Intra-cellular Cytokine Staining (ICS) Analysis
Multiparameter flow cytometry was performed to study the
efficacy of vaccination regimes in altering the magnitude and
polyfunctionality of CD8
+ T-cells, as previously described [32].
Groups of mice (4 per group) were inoculated with different
combination of immunogens, VLP-PYCS/VLP-PYCS (50 mg
each time), VLP-PYCS (50 mg)/MVA-PYCS (10
7 pfu), DNA-
PYCS (100 mg)/MVA-PYCS (10
7 pfu), non-recombinant VLP/
VLP (50 mg each) and PBS/PBS. Following immunization, the
animals were sacrificed after 56 days post-boost to study memory
responses. Splenocytes (4610
6) from the sacrificed animals were
stimulated with 1 mg/ml of CS specific CD8 peptide (SYVP-
SAEQI) along with Brefeldin (1 mg/ml) (BD Bioscience) for
6 hours in a 96 well plate. After incubation, the cells were washed
twice with PBS and stained with LIVE/DEAD fixable dead cell
stain kit, following which, the cells were washed and blocked with
CD16/CD32 antibody (Fc Block; BD Bioscience). The cells were
then stained for surface markers with CD4-Alexa 700, CD8-V500,
CD127-V450 and CD62L-FITC (BD Bioscience). This was
followed by permeabilisation using BD Cytofix/Cytoperm
TM Kit
(Becton Dickinson) and staining for intracellular cytokines using
IFN-c PeCy7, TNF-a PE and IL-2 APC. Nearly 50,000 cells were
then passed through LSRII flow cytometer (Becton Dickinson).
The data generated were analyzed using Flo-Jo (Tree Star. Inc)
and SPICE (ver 5.0).
Quantitation of liver stages
At 42 h following sporozoite challenge, livers were removed and
P. yoelii liver-stage parasites were measured by quantification of
parasite-specific 18S rRNA in total liver RNA as described
elsewhere [20]. Livers were homogenized in a Ten Broeck tissue
grinder (VWR Scientific) in 4 ml of a denaturing solution (4 M
guanidinium thiocyanate, 25 mM sodium citrate [pH 7], 0.5%
sarcosyl) made fresh as a working solution (50 ml of denaturing
solution, 0.2 M -2-mercaptoethanol). Total liver RNA was then
isolated from the liver homogenate by using the TRIzol reagent
(Gibco/BRL, Grand Island, N.Y.) as outlined in the product
insert. One microgram of RNA was treated with 1.0 U of DNase I
(Boehringer Mannheim, Mannheim, Germany) and was then
converted to cDNA by the Superscript preamplification system for
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in a 21-ml total volume as outlined in the product insert.
For quantification of parasite-specific rRNA by quantitative-
competitive reverse transcription-PCR (RT-PCR)[21], parasite-
specific rRNA was amplified from 5 ml of the cDNA mixture in a
PCR master mix containing 46 ml of PCR Supermix (Gibco/
BRL), 1 ml each of parasite-specific primers PB1 and PB2 (1)
(12 mM, final concentration), 0.2 ml (1 U) of Taq DNA polymerase
(Sigma, St. Louis, Mo.), and 1 ml of a known concentration of
competitor plasmid. Then 35 cycles of amplification in a PCR
Express (Hybaid, Middlesex, United Kingdom) thermocycler were
performed under the following conditions: 94uC for 1 min, 60uC
for 2 min, and 72uC for 1 min. An initial denaturation step at
94uC for 2 min and a terminal elongation step at 72uC for 10 min
were also included. Target and competitor amplicons were
resolved on ethidium bromide-stained 2% agarose gels and
photographed by the Eagle Eye II still video system (Stratagene,
La Jolla, California), and the image was stored electronically.
Target-to-competitor ratios were then determined using the NIH
Image software program. We performed a series of amplifications
with different competitor concentrations and used target-to-
competitor ratios from each competitor concentration in linear
regression analysis to determine the competitor concentration
where target and competitor amplicon ratios were equivalent. This
concentration was used as a relative measure of liver parasite
burden. Equal cDNA synthesis between samples was ensured by
amplification of the housekeeping ß-actin gene at PCR conditions
below saturation.
Statistical analysis
Statistical analysis of ELISPOT and protection assays was
performed by a one-way ANOVA with Tukey post test and
Bonferroni correction to all groups. For the statistical analysis of
ICS data we used a novel approach that corrects measurements
for the medium response (RPMI) and at the same time allows the
calculation of confidence intervals and p-values of hypothesis tests
[33]. The background for the different cytokines in the
unstimulated controls never exceeded 0.05%. The data analysis
program, Simplified Presentation of Incredibly Complex Evalua-
tions (SPICE, version 4.1.5, Mario Roederer, Vaccine Research
Center, NIAID, NIH), was used to analyze and generate graphical
representations of T cell responses detected by polychromatic flow
cytometry. All values used for analyzing proportionate represen-
tation of responses are background-subtracted. In all cases, P
values of less than 0.05 were considered statistically significant. All
statistic tests were performed using GraphPad Prism version 4.03
for Windows (GraphPad Software, San Diego, C).
Table 1. Dosage of different vaccination regimes: A summary of priming and boosting agents used in the study with the
corresponding dosages.
Experiment Priming Boosting Number of mice
Agent Dose Agent Dose
IFN-c ELISPOT VV-PYCS 10
7 PFU VV-PYCS 10
7 PFU 5
PPV
1 10 mg VV-PYCS 10
7 PFU 5
PPV 50 mg VV-PYCS 10
7 PFU 5
PPV 10 mg MVA-PYCS 10
7 PFU 5
PPV 50 mg MVA-PYCS 10
7 PFU 5
PPV 100 mg MVA-PYCS 10
7 PFU 5
PPV 10 mg VV-LUC 10
7 PFU 5
– MVA-PYCS 10
7 PFU 5
nrPPV
2 50 mg MVA-PYCS 10
7 PFU 5
PPV 10 mg PPV 10 mg5
PPV 100 mg PPV 100 mg5
Intra-cellular Cytokine Staining
(ICS)
PPV 50 mg PPV 50 mg4
PPV 50 mg MVA-PYCS 10
7 PFU 4
DNA-PYCS 100 mg MVA-PYCS 10
7 PFU 4
nrPPV 50 mg nrPPV 50 mg4
PBS PBS 4
Challenge Studies VV-PYCS 10
7 PFU VV-PYCS 10
7 PFU 5
PPV 10 mg VV-PYCS 10
7 PFU 5
PPV 50 mg VV-PYCS 10
7 PFU 5
PPV 50 mg MVA-PYCS 10
7 PFU 5
FLU-PYCS 10
7 PFU MVA-PYCS 10
7 PFU 5
PPV 10 mg PPV 10 mg5
––5
All agents were administered s.c except for DNA-PYCS which was injected intradermally.
1PPV refers to PPV-VLPs containing the CD8 epitope of P.yoelii CS protein.
2nrPPV refers to non-recombinant PPV-VLPs.
doi:10.1371/journal.pone.0034445.t001
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